We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.


Any AUS or NZ company


Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names


Shareholder links

Our website ranking of AGH: rating 5
(5 out of 5)



Computershare, Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000022774
Address: Suite 2, Level 37 360 Elizabeth Street Melbourne, VIC 3000
Tel:  1300 70 20 20 Fax: 03 8672 7687

Date first listed: 21/09/2018
Company Secretary: Robert Meissner
Sector:  Industry Group: 
Activities: Holding company of Althea Company Limited which holds a number of licenses and permits for the importation, cultivation, production and supply of medicinal cannabis in Australia

News & Events

Expand this box to read and print

The suspension of trading in the securities of Althea Group Holdings Limited will be lifted immediately, following the release by AGH of an announcement regarding an acquisition and capital raising.


Althea agrees to acquire Canadian extraction and contract manufacturing company Peak Processing Solutions, founded by four former senior personnel from Aphria Inc. Althea has opened one of the UK's first cannabis destination clinics in central London and plans to open two further clinics in Q3 CY2019. In July 2019, Althea received a UK import licence for the first shipment of medicinal cannabis products from Australia. Althea is in advanced negotiations regarding a 50/50 joint venture to establish cultivation, extraction and manufacturing (EU GMP) facilities in Portugal. Althea has received commitments for a A$30m capital raising to fund the acquisition and further growth initiatives.


The securities of Althea Group Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AGH, pending the release of an announcement regarding an acquisition and capital raising.


The Drug Science Medical Cannabis Working Group, which includes the United Patients Alliance, is launching the UK's first national pilot for medical cannabis. The pilot aims to enrol 20,000 patients before the end of 2021 and will use a real word data patient registry to assess efficacy, safety and patient-reported outcomes in patients prescribed medical cannabis. Althea has been selected from a limited number of medicinal cannabis companies, to supply its range of products to the pilot.


Althea receives its first patient prescription for medicinal cannabis in the UK. Planning permit granted for Althea's Cultivation and Manufacturing facility.


1,000 patients have now been prescribed Althea medicinal cannabis products in Australia. 185 Healthcare Professionals have prescribed Althea medicinal cannabis. Althea is averaging more than 11 new patients per business day, including 227 additional patients in May. Althea has achieved the 1,000 patient milestone five months ahead of schedule.


The company releases its PAC Partners Hong Kong Conference Presentation.


Althea has been granted a Hemp Cultivation Licence allowing the cultivation and processing of low-THC (Hemp) cannabis. Althea has entered into an exclusive agreement with Tissue Culture Australia related to the development of tissue culture protocols for cannabis. The Hemp Cultivation Licence also presents commercial opportunities for Althea in Hemp foods and Isolated-CBD markets including Europe and the USA.


Althea Concierge UK launches successfully with doctors already commencing their first assessments of patients for Althea medical cannabis products. Althea Concierge UK streamlines the prescription process and facilitates patient referrals from primary care doctors to Althea UK specialist prescribers. Althea and Drug Science joint educational meetings to be held in June are oversubscribed, with nearly 300 healthcare professionals registered to attend. Althea sponsored and participated in the recent IOTOD conference in Germany.


The company releases its Securities Dealing Policy.


651 Patients have now been prescribed Althea medicinal cannabis products. 145 Healthcare Professionals have prescribed Althea medicinal cannabis. 140 patients were added between April 4 and April 26 (inclusive), representing 10 new patients per business day. Australia the fastest growing global market in the world (by percentage month-on-month growth). Althea currently recruiting additional staff to capitalise on increased demand.


The company lodges its Appendix 4C - quarterly.


The company provides an investor update.


The company lodges its Half Year Accounts and Report.


The company lodges an Appendix 4D.


Althea has signed a product supply and distribution agreement with Cannvalate, providing Althea with access and support to one of Australia's largest network of medicinal cannabis prescribing clinics. 354 Patients have now been prescribed Althea's medicinal cannabis products. 109 Healthcare Professionals are prescribing Althea's products in Australia.


The company co-launches online portal for free RACGP accredited medical cannabis education.


The company announced expansion and extension of its patient acquisition model into the U.K. through the acquisition of a new UK subsidiary company, Althea MMJ UK Ltd.


The company lodges its Appendix 4C - Quarterly.


Althea has achieved the 300 patient milestone with 86 registered Healthcare Professionals now prescribing Althea products throughout Australia. Althea has also signed an agreement with Cannabis Access Clinics, one of the region's largest medicinal cannabis destination clinic networks, for the education of doctors.


Althea has received its largest medicinal cannabis shipment to date from its major Canadian supplier, Aphria Inc.


The company releases an Investor Presentation - December 2018.


The company releases the results of its meeting.


The company releases the CEO Address to Shareholders.


Althea granted Licence to Export medicinal cannabis. Althea supply to domestic patients continues to grow, with 156 patients and 54 prescribers in its network. Planning permit lodged for ODC approved production facility.


Althea was granted medicinal cannabis Manufacture Licence. Manufacture Licence allows the manufacture of extracts and tinctures of cannabis and cannabis resin, in accordance with relevant manufacture permits. Althea now holds an Import Licence, a Medicinal Cannabis Licence (cultivation and production) and a Manufacture Licence.


The company releases a notice of meeting. The AGM will be held on Friday, 30 November 2018 at 2.00pm (AEDT) at Norton Rose Fulbright Australia Level 15, RACV Tower 485 Bourke Street, Melbourne, Victoria 3000.


The company lodges an Appendix 4C - quarterly.


100 patients were approved for Althea medicinal cannabis products since May 2018. There are 42 doctors prescribing Althea products throughout Australia. 100% approval rate for TGA applications to prescribe Althea products.


Althea signs distribution agreement with major independent cannabis distributor, Health House International. The agreement enhances Althea's national sales footprint and extends coverage to include Western Australia.


listed entity carried for record purposes only



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    25/10/2019Andrew Newbold250,000$0.400$100,000
    25/10/2019Alan Boyd250,000$0.400$100,000
    25/10/2019Joshua Fegan50,000$0.400$20,000
    22/10/2019Andrew Newbold180,000$1.000$180,000
    22/10/2019Penelope Dobson30,000$1.000$30,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Andrew NewboldChairman, Independent Director21/06/2018
    Joshua FeganManaging Director, CEO21/06/2018
    Robert MeissnerCFO15/10/2018
    Alan BoydIndependent Director21/06/2018
    Penelope DobsonNon Exec Director30/11/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Gregg BattersbyNon Exec Director21/06/201804/03/2019

    Date of first appointment, title may have changed.